Sources of variability in quantification of CMR infarct size and their impact on sample size calculations -reproducibility among three core laboratories 
Background
Infarct size is increasingly used as an efficacy endpoint in randomized trials comparing acute myocardial infarct (AMI) therapies. Infarct size, depicted by delayedenhancement-CMR, is quantified using manual planimetry (MANUAL), visual scoring (VISUAL), or automated techniques using signal-intensity thresholding to define infarct borders (AUTO). Although AUTO is considered the most reproducible, prior studies did not account for the subjective determination of endocardial/epicardial borders, which all methods require. For MANUAL and VISUAL, prior studies have not explicitly defined how to treat intermediate signal-intensities due to partial volume. We wanted to assess sources of variability among 6 methods in quantification of AMI size, and illustrate the significance of these findings on sample size calculations for clinical trials.
Methods
Scans of 30 AMI patients and 12 controls were sent to 3 core-laboratories. Infarct size was measured using 6 methods, each separated by >2-months time, as follows ( n=540 evaluations , respectively). For these 3 techniques the within-patient variability due to the quantification method was less than 10% of the total variability. Hence, there were minimal differences between these methods in the calculated sample sizes needed to detect a 3%, 5%, and 7% absolute reduction in acute infarct size.
Conclusions
Among CMR core-laboratories, an important source of variability in infarct size quantification is the subjective delineation of endocardial/epicardial borders. When intermediate signal intensities are considered in manual 
